Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIAlta high-dose rifampicin study in difficult-to-treat drug-susceptible tuberculosis
NL-OMON59208Phase 2Recruiting
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rifampicin in Tuberculosis (TB) and drug-susceptible tuberculosis (DS-TB), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Severe adverse event rate at 8 weeks. Started Feb 2025; status: recruiting.
02
Drugs
rifampicin
03
Conditions
Tuberculosis (TB)drug-susceptible tuberculosis (DS-TB)
Beyond the preview
Go deeper on NL-OMON59208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59208.